Merck & Co Maps Out Route To $10bn Cardiovascular Franchise

Eight Approvals Targeted By 2030

The US pharma giant is planning ahead for Keytruda’s swansong, and hopes that wave of new cardiovascular drugs can help maintain its growth into the next decade.

Merck & Co.
Merck & Co. is building q case for a post-Keytruda portfolio including big-earning cardiovascular drugs, but analysts are yet to buy into its $10bn plus projections. • Source: Alamy

Merck & Co needs to find a way to grow its business once its blockbuster cancer immunotherapy Keytruda hits patent expiry in 2028, and believes a wave of new cardiovascular drugs could help it achieve that goal.

More from Business

Baxdrostat, AstraZeneca’s Next Big CVRM Bet

 
• By 

The firm has lofty ambitions for the aldosterone synthase inhibitor to treat hypertension and kidney disease.

Stock Watch: How Tariff Threat Might Boost Pharma Q1

 
• By 

Supply chain disruption fears at the start of the COVID-19 pandemic caused drug over-ordering. Imminent tariffs on drugs may have had a similar effect on pharma sales in Q1 earnings season.

Peter Marks’ Departure From FDA Rattles Biopharma Industry

 
• By 

Stock prices plummeted, particularly for vaccine makers and cell and gene therapy developers, after the US FDA’s top biologics overseer resigned over vaccine misinformation concerns.

Vertex Ends One Type 1 Diabetes Cell Therapy, Shifts Focus To Another

 
• By 

Seeking cell therapy approaches to cure type 1 diabetes, Vertex abandons a candidate encapsulated to avoid immune system detection but hopes to file another candidate for approval in 2026.

More from Scrip

Vertex Ends One Type 1 Diabetes Cell Therapy, Shifts Focus To Another

 
• By 

Seeking cell therapy approaches to cure type 1 diabetes, Vertex abandons a candidate encapsulated to avoid immune system detection but hopes to file another candidate for approval in 2026.

Isomorphic Adds To Growing AI War Chest With First External Funding Round

 

The four-year-old firm said it plans to advance programs toward the clinic from the funding round, which comes just over a year after signing two major pharma partnerships.

Corcept’s Relacorilant Shows Benefit In Ovarian Cancer, Expanding Pipeline Opportunity

 

A Phase III trial testing the cortisol modulator showed a benefit on PFS and OS in patients with platinum-resistant ovarian cancer.